Hepatitis C News and Research

Latest Hepatitis C News and Research

XTL Biopharmaceuticals completes $2.4 million private placement of securities

XTL Biopharmaceuticals announced yesterday, March 18, 2012, it successfully completed a private placement of securities with foreign as well as Israeli institutional and private investors for a total of $2.4 million (NIS 9.1 million).

19 Mar 2012

EORTC, EASL publish first joint CPGs on management of hepatocellular carcinoma

The European Association for the Study of the Liver (EASL) and the European Organisation for Research and Treatment of Cancer (EORTC) today publish their first joint Clinical Practice Guidelines (CPGs) on the management of hepatocellular carcinoma.

16 Mar 2012

More women need regular checks for Chlamydia infection: CDC

According to new figures from the Centers for Disease Control and Prevention (CDC), not many young, sexually active women in the United States are getting screened for chlamydia.

15 Mar 2012

GenMark Diagnostics fourth quarter revenues increase to $2.0 million

GenMark Diagnostics, Inc. today reported additional financial information for the fourth quarter ended December 31, 2011 that was unavailable at the time it released preliminary financial results on March 8, 2012.

15 Mar 2012

Linking HCV infected people with care is key to reducing related mortality and morbidity

Broader screening to identify people infected with hepatitis C virus (HCV) would likely be cost effective, according to a new report published in Clinical Infectious Diseases.

15 Mar 2012

China Pharma revenue increases 9% to $81.2M for full year 2011

China Pharma Holdings, Inc., a fully-integrated specialty pharmaceuticals company in China, today announced financial results for the year ended December 31, 2011.

15 Mar 2012

Inovio achieves strong T cell immune responses in PENNVAX-B Phase I HIV study

Inovio Pharmaceuticals, Inc. announced today that it has achieved strong T cell immune responses in a Phase I clinical study of PENNVAX-B, its product for the treatment of the HIV subtype prevalent in North America and Europe, in HIV-positive subjects.

13 Mar 2012

Medivir initiates two new HPC3001 and HPC3011 phase III trials in HCV

MedivirAB a research based specialty pharmaceutical company focused on infectious diseases announces that its oral, once daily investigational protease inhibitor TMC435, developed by Janssen Pharmaceuticals for the treatment of Hepatitis C virus (HCV), has commenced patient dosing and started screening in two new phase III clinical trials, HPC3001 and HPC3011, respectively.

13 Mar 2012

U-M to research into treatment for hepatitis C

The Greenview Foundation has announced a gift of $57,000 to the University of Michigan Health System to support research on a treatment for hepatitis C.

12 Mar 2012

CDC launches new campaign to combat HIV among African-American women

To combat the high toll of HIV and AIDS among black women in the United States, the Centers for Disease Control and Prevention today launched Take Charge. Take the Test., a new campaign to increase HIV testing and awareness among African-American women.

12 Mar 2012

Cancer rates to fall among men but slightly rise among women by 2020: Report

The report says that due to the growing and ageing population the actual number of new cases will rise by almost 40 per cent on 2007 levels. But when that's converted to the number of cases per 100,000 people the results are surprising. Cancer rates in men will fall from 595 to 568 cases per 100,000 by 2020. That equates to about 85,000 cases. When it comes to women the rate is projected to rise from 394 to 408 cases per 100,000. That's equivalent to 65,000 new cases in 2020.

11 Mar 2012

GenMark Diagnostics fourth quarter revenues increase to $2.0M

GenMark Diagnostics, Inc. today reported preliminary financial results for the fourth quarter and fiscal year ended December 31, 2011. The Company will release its full financial statements and related disclosures along with its Form 10-K filing for the period ending December 31, 2011 upon completion of its independent audit, which includes the Company's first Sarbanes-Oxley audit of internal controls, by March 15, 2012.

9 Mar 2012

Enzo Biochem to unveil data on AmpiProbe HCV assay at ESCMID meeting

Enzo Biochem Inc. announced today that the company will present for the first time peer-reviewed data on detection of hepatitis C virus (HCV) using its novel AmpiProbe technology platform, which provides low cost and high sensitivity real-time nucleic acid amplification assays.

9 Mar 2012

Russia should abandon 'zero-tolerance' approach to drug use and implement proven prevention strategies

Why have effective, "simple tools such as Medication Assisted Therapy and clean needle-exchange services" -- methods that are "very effective in decreasing drug abuse and reducing risk of infection with HIV, hepatitis C and other diseases" – "had so little impact on the policies and programs of the Russian Federation?" Bertrand Audoin, executive director of the International AIDS Society, and Chris Beyrer, a professor at the Johns Hopkins Bloomberg School of Public Health, write in this New York Times opinion piece.

6 Mar 2012

Sun-dried tomatoes may be contaminated with hepatitis A virus: Officials warn

The Health Protection Agency (HPA) said two confirmed cases of the infection had been found to have an identical strain to three cases reported in England and confirmed at HPA Colindale in 2010. Both people had recently eaten sun-dried tomatoes.

5 Mar 2012

FDA confirms FluCide pre-IND meeting date with NanoViricides

NanoViricides, Inc. announced today that March 29th, 2012 has been confirmed by the US FDA as the date for its initial meeting with the Company's scientists. This pre-IND meeting will focus on FluCide, designated as NV-INF-1, the Company's novel anti-influenza drug.

5 Mar 2012

Inovio's SynCon vaccine for HPV types 6 and 11 induces CD8+ T cells in mice

Inovio Pharmaceuticals, Inc. announced today that its SynCon therapeutic vaccine for human papillomavirus (HPV) types 6 and 11, which are associated with head & neck cancers and genital warts, among other conditions, induced strong antigen-specific CD8+ T cells in mice.

5 Mar 2012

GVDI develops PERCUGUARD needlestick prevention device

Golden Valley Development, Inc. is pleased to announce the development of the PERCUGUARD needlestick prevention device, a tool currently unavailable in the medical and dental industries, exceeding 1 billion potential annual applications worldwide.

5 Mar 2012

Scientists discover how to enhance production of hepatocytes to repair damaged liver tissue

Scientists have shed light on how the liver repairs itself with research that could help develop drugs to treat liver disease.

4 Mar 2012

Europe conference to discuss on new HIV indicator diseases

Today, heterosexuals in Europe are at particular risk of carrying HIV for so long that they remain undiagnosed until their immune system starts to fail and they become ill. An international study under the leadership of the HIV in Europe initiative has now revealed that a number of diseases, including herpes zoster and certain forms of cancer, should be on the list of indicators for having HIV - and thus serve to prompt health care professionals to suggest an HIV-test to their patients.

2 Mar 2012